Liabilities, Current of Aspire Biopharma Holdings, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary: Aspire Biopharma Holdings, Inc. quarterly Liabilities, Current in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
Aspire Biopharma Holdings, Inc. Liabilities, Current for the quarter ending 30 Sep 2025 was $13,860,506, a 111% increase year-over-year.
Source SEC data: View on sec.gov

Liabilities, Current, Quarterly (USD)

Liabilities, Current, YoY Quarterly Change (%)

Aspire Biopharma Holdings, Inc. Quarterly Liabilities, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$13,860,506	+$7,287,625	+111%	30 Sep 2025	10-Q/A	14 Nov 2025	2025	Q3
Q2 2025	$10,556,922	+$4,316,642	+69%	30 Jun 2025	10-Q	13 Aug 2025	2025	Q2
Q1 2025	$9,868,953	+$7,235,570	+275%	31 Mar 2025	10-Q/A	13 Aug 2025	2025	Q1
Q4 2024	$1,688,077	+$1,284,749	+319%	31 Dec 2024	10-Q/A	14 Nov 2025	2025	Q3
Q3 2024	$6,572,881	+$6,256,565	+1978%	30 Sep 2024	10-Q	14 Nov 2024	2024	Q3
Q2 2024	$6,240,280	+$5,955,924	+2095%	30 Jun 2024	10-Q	16 Aug 2024	2024	Q2
Q1 2024	$2,633,383	+$2,276,962	+639%	31 Mar 2024	10-Q	05 Jun 2024	2024	Q1
Q4 2023	$403,328	+$100,005	+33%	31 Dec 2023	10-K	07 Apr 2025	2024	FY
Q3 2023	$316,316	+$127,611	+68%	30 Sep 2023	10-Q	08 Nov 2023	2023	Q3
Q2 2023	$284,356	+$137,890	+94%	30 Jun 2023	10-Q	08 Aug 2023	2023	Q2
Q1 2023	$356,421	+$304,665	+589%	31 Mar 2023	10-Q	11 May 2023	2023	Q1
Q4 2022	$303,323	+$9,627	+3.3%	31 Dec 2022	10-K	11 Mar 2024	2023	FY
Q3 2022	$188,705			30 Sep 2022	10-Q	10 Nov 2022	2022	Q3
Q2 2022	$146,466			30 Jun 2022	10-Q	11 Aug 2022	2022	Q2
Q1 2022	$51,756			31 Mar 2022	10-Q	16 May 2022	2022	Q1
Q4 2021	$293,696			31 Dec 2021	10-K	21 Mar 2023	2022	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.